All In Biotech

Drug Trial Radar · NCT04175171

Clinical Trial of Comparative Study of GB221 Pharmacokinetics

A Randomized, Double-blind, Parallel-group, Comparative Phase I Study to Evaluate the Safety and Pharmacokinetics of Single Intravenous (IV) Administration of GB221 Versus Herceptin® (Trastuzumab)

Last checked: Nov 19, 2026Latest source record: Dec 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Nov 7, 2011

Primary completion

Jan 8, 2012

Study completion Mar 8, 2012

Sponsor

Lead sponsor
Genor Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective is to assess the safety of a single dose of GB221 compared to Herceptin® when administered as a single IV injection at a dose of 8 mg/kg. The secondary objective of the study is to assess the pharmacokinetics of GB221 compared to Herceptin®.

Conditions

  • Metastatic Breast Cancer

Interventions

  • Coprelotamab InjectionDrug

    The single intravenous infusion of 8mg/kg Coprelotamab shall be administered within 90 minutes through infusion pump.

  • Trastuzumab InjectionDrug

    The single intravenous infusion of 8mg/kgTrastuzumab shall be administered within 90 minutes through infusion pump.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. physical examinationTime frame: Up to 84 days
  2. adverse eventTime frame: Up to 84 days
  3. blood pressureTime frame: Up to 84 days
  4. heart rateTime frame: Up to 84 days
  5. respiration rateTime frame: Up to 84 days
  6. oxygen saturationTime frame: Up to 84 days
  7. temperatureTime frame: Up to 84 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Linear Clinical Research Limited

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.